A carregar...
SUN-098 Low-Dose Infigratinib Treatment Does Not Lead to Changes in Phosphorous Preclinically in Mice
BACKGROUND: Infigratinib (BGJ398) is a potent and selective FGFR1-3 inhibitor under evaluation for the treatment of achondroplasia, the most common form of disproportionate short stature. Low doses of infigratinib were shown to be effective in improving skeletal abnormalities in a mouse model of ach...
Na minha lista:
| Publicado no: | J Endocr Soc |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Oxford University Press
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7208254/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jendso/bvaa046.552 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|